Found: 151
Select item for more details and to access through your institution.
Response to letter to the editor regarding "Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data".
- Published in:
- Pharmacoepidemiology & Drug Safety, 2022, v. 31, n. 1, p. 110, doi. 10.1002/pds.5376
- By:
- Publication type:
- Article
Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 7, p. 918, doi. 10.1002/pds.5257
- By:
- Publication type:
- Article
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
- Published in:
- Diabetologia, 2022, v. 65, n. 12, p. 1925, doi. 10.1007/s00125-022-05787-2
- By:
- Publication type:
- Article
Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials.
- Published in:
- Diabetologia, 2020, v. 63, n. 8, p. 1516, doi. 10.1007/s00125-020-05174-9
- By:
- Publication type:
- Article
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
- Published in:
- Diabetologia, 2017, v. 60, n. 9, p. 1601, doi. 10.1007/s00125-017-4361-9
- By:
- Publication type:
- Article
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2017, doi. 10.1111/dom.15533
- By:
- Publication type:
- Article
Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta‐analysis of trials investigating intensive glucose‐lowering strategies in people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2069, doi. 10.1111/dom.15511
- By:
- Publication type:
- Article
Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta‐analysis of cardiovascular outcome trials of novel glucose‐lowering agents.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 5, p. 1837, doi. 10.1111/dom.15500
- By:
- Publication type:
- Article
Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2084, doi. 10.1111/dom.15079
- By:
- Publication type:
- Article
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1385, doi. 10.1111/dom.14990
- By:
- Publication type:
- Article
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2297, doi. 10.1111/dom.14830
- By:
- Publication type:
- Article
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2071, doi. 10.1111/dom.14805
- By:
- Publication type:
- Article
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1338, doi. 10.1111/dom.14710
- By:
- Publication type:
- Article
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 11, p. 2572, doi. 10.1111/dom.14504
- By:
- Publication type:
- Article
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 9, p. 2177, doi. 10.1111/dom.14453
- By:
- Publication type:
- Article
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1588, doi. 10.1111/dom.14372
- By:
- Publication type:
- Article
Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1331, doi. 10.1111/dom.14345
- By:
- Publication type:
- Article
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 136, doi. 10.1111/dom.14202
- By:
- Publication type:
- Article
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2170, doi. 10.1111/dom.14136
- By:
- Publication type:
- Article
iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1683, doi. 10.1111/dom.14077
- By:
- Publication type:
- Article
Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1567, doi. 10.1111/dom.14068
- By:
- Publication type:
- Article
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 873, doi. 10.1111/dom.13957
- By:
- Publication type:
- Article
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
- By:
- Publication type:
- Article
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 10, p. 2203, doi. 10.1111/dom.13804
- By:
- Publication type:
- Article
Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 11, p. 2680, doi. 10.1111/dom.13438
- By:
- Publication type:
- Article
More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2314, doi. 10.1111/dom.13368
- By:
- Publication type:
- Article
A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, p. 22, doi. 10.1111/dom.13162
- By:
- Publication type:
- Article
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 11, p. 1529, doi. 10.1111/dom.12963
- By:
- Publication type:
- Article
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 10, p. 1408, doi. 10.1111/dom.12961
- By:
- Publication type:
- Article
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 5, p. 672, doi. 10.1111/dom.12872
- By:
- Publication type:
- Article
Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
- Published in:
- Clinical Diabetes, 2018, v. 36, n. 2, p. 138, doi. 10.2337/cd17-0065
- By:
- Publication type:
- Article
Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 5, p. 915, doi. 10.1007/s13300-023-01389-2
- By:
- Publication type:
- Article
Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 4, p. 1007, doi. 10.1007/s13300-020-00797-y
- By:
- Publication type:
- Article
Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 1, p. 327, doi. 10.1007/s13300-018-0544-8
- By:
- Publication type:
- Article
Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 2155, doi. 10.1007/s13300-018-0507-0
- By:
- Publication type:
- Article
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Abstract 122: Multifactorial risk reduction with oral semaglutide vs comparators in the treatment of type 2 diabetes.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2022, v. 26, p. 52, doi. 10.4103/2230-8210.363626
- By:
- Publication type:
- Article
Use of comprehensive recruitment strategies in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) multi-center clinical trial.
- Published in:
- Clinical Trials, 2023, v. 20, n. 5, p. 546, doi. 10.1177/17407745231175919
- By:
- Publication type:
- Article
Establishing an electronic health record–supported approach for outreach to and recruitment of persons at high risk of type 2 diabetes in clinical trials: The vitamin D and type 2 diabetes (D2d) study experience.
- Published in:
- Clinical Trials, 2019, v. 16, n. 3, p. 306, doi. 10.1177/1740774519839062
- By:
- Publication type:
- Article
663-P: Achievement of Near-Normal HbA1c with Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-663-P
- By:
- Publication type:
- Article
664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-664-P
- By:
- Publication type:
- Article
661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-661-P
- By:
- Publication type:
- Article
618-P: Association between Time-in-Range and A1C in Basal Insulin-Treated People with Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-618-P
- By:
- Publication type:
- Article
617-P: Association between Change in Time-in-Range and A1C in Basal Insulin-Treated People with Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-617-P
- By:
- Publication type:
- Article
606-P: Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-606-P
- By:
- Publication type:
- Article
959-P: Indirect Treatment Comparison (ITC) of IGlarLixi vs. IDegLira in Adults Inadequately Controlled by GLP-1 Receptor Agonists (GLP-1RAs).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-959-P
- By:
- Publication type:
- Article
956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-956-P
- By:
- Publication type:
- Article
932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-932-P
- By:
- Publication type:
- Article
933-P: Greater Reductions in HbA1c and Body Weight with Once-Weekly Semaglutide vs. Comparators across Baseline BMI Subgroups: A Post Hoc Analysis of SUSTAIN 1-5 and 7-10.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-933-P
- By:
- Publication type:
- Article